サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584115

α1アンチトリプシン欠乏症治療市場：治療タイプ別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測

Alpha-1 Antitrypsin Deficiency Disease Treatment Market, By Treatment Type, By Route of Administration, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 288 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
α1アンチトリプシン欠乏症治療市場：治療タイプ別、投与経路別、エンドユーザー別、国別、地域別 - 産業分析、市場規模、市場シェア、2024-2032年予測
出版日: 2024年10月26日
発行: AnalystView Market Insights
ページ情報: 英文 288 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

α1アンチトリプシン欠乏症治療市場規模は2023年に26億3,043万米ドルとなり、2024年から2032年にかけてCAGR 10.10％で拡大

α1アンチトリプシン欠乏症治療市場-市場力学

遺伝子疾患に対する認識の高まりがα1アンチトリプシン欠乏症治療市場の成長を促進

遺伝子疾患に対する意識の高まりが、早期診断と効果的な管理を重視するようになり、α1アンチトリプシン（AAT）欠乏症治療市場の成長を促進しています。AAT欠乏症は肺と肝臓の健康に影響を及ぼす遺伝的疾患であるため、多くの保健機関や政府が検診プログラムを拡大し、そのリスクについて国民を教育するよう促しています。例えば、世界保健機関（WHO）は、遺伝性疾患の発見における遺伝子検査の重要性を強調しています。製薬会社もまた、革新的な治療法を生み出すべく研究開発を加速させています。このような意識の高まりは、的を絞った治療に対する需要の高まりと、世界中のAAT欠乏症患者の医療アクセスの改善につながっています。

α1アンチトリプシン欠乏症治療市場-主要洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024-2032年）に約10.10%のCAGRで毎年成長すると推定されています。

治療タイプ別では、増強療法が2023年に最大の市場シェアを示すと予測されています。

投与経路別では、静脈内投与が2023年の主要タイプでした。

地域別では、北米が2023年の主要収益源でした。

α1アンチトリプシン欠乏症治療市場-セグメンテーション分析：

世界のα1アンチトリプシン欠乏症治療市場は、治療タイプ、投与経路、エンドユーザー、地域に基づいてセグメント化されます。

市場は治療タイプに基づいて4つのカテゴリーに分けられる：すなわち、補強療法、気管支拡張剤療法、酸素療法、ステロイド療法です。補強療法は、AATレベルの補充に直接的な役割を果たすため、最も優先順位が高いです。気管支拡張療法は症状管理に使用され、酸素療法とステロイド療法は重症例に使用されます。

市場は投与経路によって3つのカテゴリーに分けられる：静脈内投与、経口投与、吸入投与です。静脈内投与が最も優先されるのは、増強療法を実施する際の有効性によるものです。経口投与は使いやすさからこれに続き、吸入は特定の症例における症状緩和のために利用されます。

α1アンチトリプシン欠乏症治療市場-地理的洞察

α1アンチトリプシン（AAT）欠乏症治療市場は、北米が先進的なヘルスケアインフラを持ち、遺伝子疾患に対する認識を重視していることから、市場をリードしています。特に米国では、Alpha-1財団のような団体に支えられ、遺伝子検査や新生児スクリーニング・プログラムの増加といった取り組みが行われています。欧州もこれに追随しており、ドイツや英国などの国々がAAT欠乏症に対処するための研究開発に多額の投資を行っています。例えば、欧州呼吸器学会は、早期発見と治療の選択肢を改善するための啓発キャンペーンを積極的に推進しています。アジア太平洋地域では、ヘルスケア支出の増加と遺伝性疾患に対する意識の高まりが市場成長の原動力となっています。日本と中国は、AAT欠乏症のような遺伝性疾患のより包括的なスクリーニングを含むヘルスケアシステムの拡充を進めています。ラテンアメリカと中東・アフリカは、ヘルスケアと診断サービスへのアクセスを改善することを目的としたイニシアチブにより、徐々に牽引力を強めているが、これらの地域は認知度とインフラの面でまだ課題を抱えています。

α1アンチトリプシン欠乏症治療市場-競合情勢：

この地域ではGrifolsや武田薬品工業などの企業が有力な企業です。2023年、グリフォルス社は需要の増加に対応するため、ノースカロライナ州にプロラスチン-Cリキッド（AAT増強療法）の製造施設を拡張しました。一方、武田薬品はAAT療法ソリューションの強化を目指した共同研究に積極的に取り組んでいます。2024年、市場の主要企業であるCSLベーリングは、AAT欠乏症に関する認知度を高めるため、欧州肺財団との提携を発表しました。この提携は、特に疾患の認知度が低い地域での早期診断と治療を支援することを目的としています。アジア太平洋地域は成長しているとはいえ、まだ初期段階にあり、AAT治療へのアクセスを改善するために、現地のヘルスケア機関と世界企業との間で重要なパートナーシップが形成されています。これらの開拓は、AAT治療市場における競争優位性を世界的に推進するための戦略的イニシアチブの重要性を強調しています。

目次

第1章 α1アンチトリプシン欠乏症治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 α1アンチトリプシン欠乏症治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 α1アンチトリプシン欠乏症治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 α1アンチトリプシン欠乏症治療市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 α1アンチトリプシン欠乏症治療市場情勢

  • α1アンチトリプシン欠乏症治療薬市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 α1アンチトリプシン欠乏症治療市場-治療タイプ別

  • 概要
    • 治療タイプ別セグメントシェア分析
    • 増強療法
    • 気管支拡張療法
    • 酸素療法
    • ステロイド療法

第8章 α1アンチトリプシン欠乏症治療市場- 投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 静脈内注射
    • 経口
    • 吸入

第9章 α1アンチトリプシン欠乏症治療市場- エンドユーザー別

  • 概要
    • エンドユーザー別セグメントシェア分析
    • 病院
    • 専門クリニック
    • ホームケア設定

第10章 α1アンチトリプシン欠乏症治療市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析- α1アンチトリプシン欠乏症治療業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Adverum Biotechnologies, Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Baxter International Inc.
    • Biogen Inc.
    • CSL Behring LLC
    • GlaxoSmithKline plc
    • Grifols SA
    • Kamada Ltd.
    • LFB Biopharmaceuticals
    • Pfizer Inc.
    • Prometic Life Sciences Inc.
    • Shire plc
    • Takeda Pharmaceutical Company Limited
    • Vertex Pharmaceuticals Incorporated
    • Others

第12章 アナリストの全方位展望

目次
Product Code: ANV4098

REPORT HIGHLIGHT

Alpha-1 Antitrypsin Deficiency Disease Treatment Market size was valued at USD 2,630.43 Million in 2023, expanding at a CAGR of 10.10% from 2024 to 2032.

The Alpha-1 Antitrypsin Deficiency (AATD) Disease Treatment Market is focused on addressing the needs of individuals with AATD, a genetic disorder that leads to the accumulation of abnormal alpha-1 antitrypsin protein in the liver, resulting in lung and liver disease. Treatments primarily include augmentation therapy, aimed at replacing the deficient protein, as well as liver and lung transplants in severe cases. Increasing awareness about genetic disorders and advancements in gene therapy are boosting research efforts in the market. Despite growing demand, limited treatment availability and high costs remain major restraints. Ongoing research into innovative therapies, such as CRISPR-based solutions, presents opportunities for expanding treatment options. According to the World Health Organization, about 1 in 2,500 individuals globally are affected by AATD, further emphasizing the need for improved and accessible treatments.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Market Dynamics

Rising Awareness of Genetic Disorders Fuels Growth in the Alpha-1 Antitrypsin Deficiency Disease Treatment Market

The rising awareness of genetic disorders is driving growth in the Alpha-1 Antitrypsin (AAT) Deficiency Disease Treatment Market, with increasing emphasis on early diagnosis and effective management. AAT deficiency, a genetic condition affecting lung and liver health, has prompted numerous health organizations and governments to expand screening programs and educate the public about its risks. For instance, the World Health Organization (WHO) has highlighted the importance of genetic testing in detecting hereditary conditions. Pharmaceutical companies are also accelerating research and development efforts to create innovative therapies. This surge in awareness is leading to greater demand for targeted treatments and improved healthcare access for AAT deficiency patients worldwide.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 10.10% over the forecast period (2024-2032)

Based on Treatment Type segmentation, Augmentation Therapy was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Intravenous was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Segmentation Analysis:

The Global Alpha-1 Antitrypsin Deficiency Disease Treatment Market is segmented on the basis of Treatment Type, Route of Administration, End-User, and Region.

The market is divided into four categories based on Treatment Type: Augmentation Therapy, Bronchodilator Therapy, Oxygen Therapy, and Steroid Therapy. Augmentation Therapy holds the highest priority due to its direct role in replenishing AAT levels. Bronchodilator Therapy is used for symptom management, while Oxygen Therapy and Steroid Therapy are used for severe cases.

The market is divided into three categories based on the Route of Administration: Intravenous, Oral, and Inhalation. The Intravenous route holds the highest priority due to its effectiveness in delivering augmentation therapy. Oral administration follows for ease of use, with Inhalation being utilized for symptom relief in specific cases.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Geographical Insights

The Alpha-1 Antitrypsin (AAT) Deficiency Disease Treatment Market shows significant geographical variation, with North America leading the market due to its advanced healthcare infrastructure and strong emphasis on genetic disorder awareness. The U.S., in particular, has seen initiatives such as increased genetic testing and newborn screening programs, supported by organizations like the Alpha-1 Foundation. Europe follows closely, with countries like Germany and the UK investing heavily in research and development to address AAT deficiency. For instance, the European Respiratory Society has been actively promoting awareness campaigns to improve early detection and treatment options. In the Asia-Pacific region, increasing healthcare expenditure and growing awareness about genetic disorders are driving market growth. Japan and China are expanding their healthcare systems to include more comprehensive screening for hereditary diseases like AAT deficiency. Latin America and the Middle East & Africa are gradually gaining traction, with initiatives aimed at improving access to healthcare and diagnostic services, although these regions still face challenges in terms of awareness and infrastructure.

Alpha-1 Antitrypsin Deficiency Disease Treatment Market- Competitive Landscape:

Companies like Grifols and Takeda Pharmaceuticals are prominent players in this region. In 2023, Grifols expanded its Prolastin-C Liquid (AAT augmentation therapy) manufacturing facility in North Carolina to meet growing demand. Meanwhile, Takeda is actively involved in research collaborations aimed at enhancing AAT therapy solutions. In 2024, CSL Behring, a key player in the market, announced a partnership with the European Lung Foundation to raise awareness about AAT deficiency. This collaboration aims to support earlier diagnosis and treatment, particularly in regions with lower disorder recognition. Asia-Pacific, though growing, remains in its early stages, with key partnerships forming between local healthcare institutions and global firms to improve access to AAT therapies. These developments underline the importance of strategic initiatives in driving competitive advantage in the AAT treatment market globally.

Recent Developments:

In January 2024, Sanofi announced its acquisition of Inhibrx, Inc., which includes the promising treatment candidate INBRX-101 for Alpha-1 Antitrypsin Deficiency (AATD). This acquisition is part of Sanofi's strategy to enhance its rare diseases and immunology portfolio.

In April 2023, Arrowhead Pharmaceuticals announced the first patient's treatment in a Phase 3 clinical study for Alpha-1 Antitrypsin Deficiency Liver Disease (AATD-LD) using their investigational therapy, Fazirsiran. This milestone triggers a $40 million payment from Takeda to Arrowhead.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Adverum Biotechnologies, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Biogen Inc.
  • CSL Behring LLC
  • GlaxoSmithKline plc
  • Grifols S.A.
  • Kamada Ltd.
  • LFB Biopharmaceuticals
  • Pfizer Inc.
  • Prometic Life Sciences Inc.
  • Shire plc
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • Others

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Augmentation Therapy
  • Bronchodilator Therapy
  • Oxygen Therapy
  • Steroid Therapy

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Intravenous
  • Oral
  • Inhalation

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Specialty Clinics
  • Homecare Settings

GLOBAL ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Treatment Type
    • 2.1.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Route of Administration
    • 2.1.3. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by End-User
    • 2.1.4. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Country
    • 2.1.5. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Market Trends

  • 3.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Opportunities
  • 3.4. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Future Trends

4. Alpha-1 Antitrypsin Deficiency Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Alpha-1 Antitrypsin Deficiency Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Landscape

  • 6.1. Alpha-1 Antitrypsin Deficiency Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 7.1.2. Augmentation Therapy
    • 7.1.3. Bronchodilator Therapy
    • 7.1.4. Oxygen Therapy
    • 7.1.5. Steroid Therapy

8. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Intravenous
    • 8.1.3. Oral
    • 8.1.4. Inhalation

9. Alpha-1 Antitrypsin Deficiency Disease Treatment Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Specialty Clinics
    • 9.1.4. Homecare Settings

10. Alpha-1 Antitrypsin Deficiency Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Alpha-1 Antitrypsin Deficiency Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Alpha-1 Antitrypsin Deficiency Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Adverum Biotechnologies, Inc.
    • 11.2.2. Arrowhead Pharmaceuticals, Inc.
    • 11.2.3. AstraZeneca PLC
    • 11.2.4. Baxter International Inc.
    • 11.2.5. Biogen Inc.
    • 11.2.6. CSL Behring LLC
    • 11.2.7. GlaxoSmithKline plc
    • 11.2.8. Grifols S.A.
    • 11.2.9. Kamada Ltd.
    • 11.2.10. LFB Biopharmaceuticals
    • 11.2.11. Pfizer Inc.
    • 11.2.12. Prometic Life Sciences Inc.
    • 11.2.13. Shire plc
    • 11.2.14. Takeda Pharmaceutical Company Limited
    • 11.2.15. Vertex Pharmaceuticals Incorporated
    • 11.2.16. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us